Building an AI infrastructure for biotech. Bacteria that munch on cancer. How to best make a cold brew. All that and more in ...
A biotech slump and scrapped federal funds are stalling a decades-long expansion, being developed by Tishman Speyer.
The diagnostics company’s stock climbed fivefold last year, but it dropped in half Friday.
Alexandria Real Estate Equities' near-term NOI and FFO outlook remains negative despite trading at a discount. Find out why ...
Pharmaceutical Technology on MSN
IQVIA to acquire Charles River drug discovery assets
The expanded offerings will allow IQVIA to serve a broader range of drug modalities and therapeutic areas.
The company was able to grow to nearly 94K SF at 681 Gateway Blvd., scoring several prime concessions along the way, including 15 months of abated rent, phased occupancy and a generous tenant ...
If 2025 had a theme for the Charlotte region's life sciences ecosystem, it was this: years of planning finally meeting their moment. From landmark facility openings to record-breaking workforce ...
Planning for phase 1/2 clinical trial initiation in Australia utilizing CYWC628 to treat diabetic foot ulcers in the first half of 2026Improved balance sheet through multiple direct offerings; complet ...
BPC Instruments AB (publ) hereby publishes the year-end report for the year 2025. The year-end report is available as an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results